38 Followers on Owler
Pulmatrix is a Massachusetts-based biopharmaceutical firm that develops and commercializes therapies for the treatment of pulmonary and non-pulmonary diseases...
Read morePulmatrix is a Massachusetts-based biopharmaceutical firm that develops and commercializes therapies for the treatment of pulmonary and non-pulmonary diseases...
Read more
News
Mar 30, 2023
PR Newswire
Press Release: Pulmatrix : Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update
Mar 30, 2023
Owler
Pulmatrix, Inc.: Pulmatrix's revenue changed from $4.82M in Sep 2022 to $6.07M in Dec 2022
Feb 06, 2023
MarketScreener
Pulmatrix: Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma
Jan 25, 2023
centralcharts
Press Release: Pulmatrix : Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"
Jan 23, 2023
centralcharts
Press Release: Pulmatrix : Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology
Jan 04, 2023
Seeking Alpha
Pulmatrix: Pulmatrix drops 18% after releasing early data for inhaled migraine therapy
Jan 04, 2023
Benzinga
Pulmatrix: Pulmatrix Says Formulated Inhaled Migraine Candidate Safe With Fewer GI Side Effects Compared To IV
Jan 04, 2023
Markets Insider
Pulmatrix: Pulmatrix Announces Positive Top Line Results In Phase 1 Study With PUR3100 For Acute Migraine
Nov 10, 2022
BioSpace
Pulmatrix: Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update
Nov 10, 2022
Owler
Pulmatrix, Inc.: Pulmatrix's revenue changed from $4.02M in Jun 2022 to $4.82M in Sep 2022
Looking for similar companies to Pulmatrix?
Pulmatrix Quarterly and Annual Revenue
Trailing 12-Months Trend (TTM)
Annual Revenue
$6.1M
Pulmatrix's revenue is the ranked 10th among it's top 10 competitors. The top 10 competitors average 46.6M. Over the last four quarters, Pulmatrix's revenue has grown by 47.2%. Specifically, in Q4 2022's revenue was $1.7M; in Q3 2022, it was $1.9M; in Q2 2022, it was $1.3M; in Q1 2022, Pulmatrix's revenue was $1.2M.
Pulmatrix News
Pulmatrix Press Releases
Pulmatrix Videos
Pulmatrix Headquarters
Pulmatrix Summary
ABOUT
Overview
Pulmatrix is a Massachusetts-based biopharmaceutical firm that develops and commercializes therapies for the treatment of pulmonary and non-pulmonary diseases. Pulmatrix was founded in 2003. Pulmatrix's headquarters is located in Lexington, Massachuse...CEO
Pulmatrix's CEO, Ted Raad, currently has an approval rating of 92%. Pulmatrix's primary competitors are Savara, TFF, Insmed and 11 more.Website
pulmatrix.comCompetitors
View 14 Pulmatrix competitors here.Acquisitions
There have been no acquisitions found related to PulmatrixInvestments
Recent investment data cannot be found related to PulmatrixFrequently Asked Questions about Pulmatrix
When was Pulmatrix founded?
Pulmatrix was founded in 2003Who is Pulmatrix's CEO?
Pulmatrix's CEO is Ted RaadHow much revenue does Pulmatrix generate?
Pulmatrix generates $6.1M in revenueHow much funding does Pulmatrix have?
Pulmatrix has historically raised $155.7M in funding
Where is Pulmatrix's headquarters?
Pulmatrix's headquarters is in Lexington Massachusetts, USAHow many employees does Pulmatrix have?
Pulmatrix has 20 employeesWho are Pulmatrix's competitors?
Pulmatrix's top competitors are Savara, TFF, Insmed